Rocket Lab (RKLB) just delivered the two numbers its shareholders want to see — record revenue and record backlog — and the stock is still down about 60% from its high and roughly a quarter off its level a month ago. That gap between the headline and the price is not confusing. It's the whole story: the demand is real, and it was never what the market was fighting over. The fight was always about the price.
What the record backlog actually buys you
The number driving the narrative is a $2.36 billion backlog, up 137% from a year ago, on top of record second-quarter revenue of $234 million, a 62% increase. Both figures came straight from Rocket Lab's own report. Backlog, for a launch-and-space-systems company, is signed contracts waiting to become revenue, so it is genuinely useful evidence: it says customers keep committing, and roughly $1 billion of it is expected to turn into revenue within the next twelve months.
That last part is the piece the story usually skips. The whole $2.36 billion book is worth only about a year of sales at the current run rate — Rocket LabRKLB-- printed $234 million in the latest quarter and guided to $250–$265 million for the next one. So this backlog is near-term revenue visibility, not a moat and not a mountain of contracted cash stretching out for decades. It tells you the next twelve months are largely spoken for. It says nothing about the years after that, which is where a valuation this size has to be earned.
Quick Backtesting Tool
The price has not fallen far enough
Here is the math that matters. Rocket Lab's market capitalization is about $37 billion. That is roughly 16 times its entire backlog and about 48 times trailing-twelve-month sales — and this is after the stock has been cut roughly in half this year.
Now the uncomfortable part of the sales multiple: it is attached to a business that is still losing money. Rocket Lab lost about $49 million in the latest quarter, and its free cash flow burn widened from roughly $77 million to $110 million a quarter. A 48x-sales price for a cash-burning company is not a discount; it is an assumption that profits show up later and grow a great deal.
That is the difference between this selloff and the setups worth buying. A stock is interesting here when the multiple sits well below the growth rate while the business funds itself. Rocket Lab is the reverse: the growth is real, but buyers are paying about 16x the entire contracted book for a company that pays its bills by selling shares.
Where the cash comes from, and what the price is really betting on
That last point deserves its own line. Rocket Lab's cash balance climbed to $2.13 billion this year, which sounds reassuring — except the increase came mostly from selling equity, not from operations. It raised about $1.53 billion through at-the-market stock offerings in the first half of 2026, taking cash from roughly $829 million at the end of 2025 to over $2 billion today. A deep balance sheet paid for with dilution is not the same as cash generated by the business, and for an already-expensive stock, each share sold makes the per-share value thinner.
So what is the market actually paying $37 billion for? The business as it exists, at roughly 16x its order book, does not get you there. The rest of the valuation is a bet on Neutron, the larger rocket that is supposed to open a new, higher-margin launch market. Neutron is the reason for the premium — and it is also the source of the risk. The vehicle's timeline has slipped from an original 2024 target to 2025, then early 2026, and now the company only expects to get it to the launch pad in the fourth quarter of 2026, with no confirmed launch date. It has already absorbed a hardware failure — a first-stage tank rupture in January traced to a manufacturing defect in a critical part.
That is the crux. Backlog growth proves demand is not the problem; nobody is arguing Rocket Lab's customers are walking away. The disagreement is whether a stock at roughly 48x trailing sales, still burning cash, and worth about 16x its entire contracted backlog deserves, even after a 60% drawdown, a price that only works if Neutron flies and mostly works for years. When the gap between the market's narrative and the math closes the other way — when the strong quarter still leaves the stock expensive — there is no edge to buy, only a risk to respect.
Rocket Lab is a fine, fast-growing company. That is separate from whether $62 is a fine price to pay. The backlog buys a year of visibility; the valuation buys a bet on a rocket that has not launched yet. A fallen stock is not automatically a cheap one, and the evidence assembled here does not support calling this dip a bargain.
